Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood derived mononuclear cell cultures

Blood

Volumn 111, Issue 5, 2008, Pages 2693-2703

  Liu, Anquan ^a,b   Claesson, Hans Erik ^b,c   Mahshid, Yilmaz ^b   Klein, George ^a   Klein, Eva ^a  

^a Tumor and Cell Biology   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Biolipox AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

KRESTIN; LEUKOTRIENE B4; THIOREDOXIN; BACTERIAL POLYSACCHARIDE; CD69 ANTIGEN; GAMMA INTERFERON; LEUKOCYTE ANTIGEN; LEUKOTRIENE B4 RECEPTOR; LTB4R PROTEIN, HUMAN; PEPTIDE FRAGMENT; T LYMPHOCYTE ANTIGEN; TRX80 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NEWBORN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UMBILICAL CORD BLOOD; VIRUS CELL INTERACTION; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; CYTOTOXICITY; DRUG EFFECT; FETUS BLOOD; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MONOCYTE; NATURAL KILLER CELL; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY; VIRUS INFECTION;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EPSTEIN-BARR VIRUS INFECTIONS; FETAL BLOOD; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LEUKOTRIENE B4; LYMPHOCYTE ACTIVATION; MONOCYTES, ACTIVATED KILLER; PEPTIDE FRAGMENTS; POLYSACCHARIDES, BACTERIAL; RECEPTORS, LEUKOTRIENE B4; T-LYMPHOCYTES; THIOREDOXINS;

EID: 40149111807     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-102319     Document Type: Article

References (44)

1. Claesson HE, Odlander B, Jakobsson PJ. Leuko-triene B4 in the immune system. Int J Immunop-harmacol. 1992;14:441-449.
2. Claesson HE. Dahlén SE. Asthma and leukotrienes: antileukotrienes as novel antiasthmatic drugs. J Intern Med. 1999;245:205-227.
3. Rola-Pleszczynski M, Bouvrette L, Gingras D, et al. Identification of interferon-gamma as the lym-phokine that mediates leukotriene B4-induced immunoregulation. J Immunol. 1987;139:513-517.
4. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003;69:123-134.
5. Spanbroek R, Hildner M, Steinhilber D, et al. 5-lipoxygenase expression in dendritic cells generated from CD34(+) hematopoietic progenitors and in lymphoid organs. Blood. 2000;96:3857-3865.
6. Miyahara N, Miyahara S, Takeda K, Gelfand EW. Role of the LTB4/BLT1 pathway in allergen-induced airway hyperresponsiveness and inflammation. Allergol Int. 2006;55:91-97.
7. Schoenberger SP. BLT for speed. Nat Immunol. 2003;4:937-939.
8. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood. 2006;107:862-869.
9. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields Virology. 4th ed. Philadelphia. PA: Lippincott, Williams, Raven; 2001:2575-2627.
10. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350:1328-1337.
11. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005;46:1-10.
12. Levitsky V, Masucci MG. Manipulation of immune responses by Epstein-Barr virus. Virus Res. 2002;88:71-86.
13. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431.
14. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617.
15. Paludan C, Munz C. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus. Curr Mol Med. 2003;3:341-347.
16. Liu A, Klein G, Bandobashi K, et al. SH2D1Aex-pression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK. Immunol Lett. 2002;80:181-188.
17. Liu A, Arbiser JL, Holmgren A, et al. PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12. Blood. 2005;105:1606-1613.
18. Pekkari K, Gurunath R, Arnér ESJ, Holmgren A. Truncated thioredoxin is a mitogenic cytokine tor resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem. 2000;275:37474-37480.
19. Pettersson A, Boketoft A, Sabirsh A, et al. First-generation monoclonal antibodies identifying the human leukotriene B4 receptor-1. Biochem Bio-phys Res Commun. 2000;279:520-525.
20. Masucci MG, Bejarano MT, Masucci G, Klein E. Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells. Cell Immunol. 1983;76:311-321.
21. Runarsson G, Liu A, Mahshid Y, et al. Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood. 2005;105:1274-1279.
22. Goldyne ME, Burrish GF, Poubelle P, Borgeat P. Arachidonic acid metabolism among human mononuclear leukocytes. Lipoxygenase-related pathways. J Biol Chem. 1984;259:8815-8819.
23. Fu Z, Cannon MJ. Functional analysis of the CD4(+)T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. J Virol. 2000; 74:6675-6679.
24. Gaudreault E, Fiola S, Olivier M, Gosselin J. Epstein-Barr virus induces MGP-1 secretion by human monocytes via TLR2. J Virol. 2007;81: 8016-8024.
25. Gosselin J, Borgeat P. Epstein-Barr virus modulates 5-lipoxygenase product synthesis in human peripheral blood mononuclear cells. Blood. 1997; 89:2122-2130.
26. Liew FY, Mclnnes IB. Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis. 2002;61 (suppl 2):ii100-102.
27. Takeda K, Tsutsui H, Yoshimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficent mice. Immunity. 1998;8:383-390.
28. Kohno K, Kataoka J, Ohtsuki T, et al. IFN-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol. 1997;158:1541-1550.
29. Linde A, Andersson B, Svenson SB, et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis. 1992;165:994-1000.
30. Hornef MW, Wagner HJ, Kruse A, Kirchner H. Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo. Clin Diagn Lab Immunol. 1995;2:209-213.
31. Setsuda J, Teruya-Feldstein J, Harris NL, et al. lnterleukin-18, interferon-gamma. IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lympho-proliferative disease. Am J Pathol. 1999;155:257-265.
32. Corsi MM, RuscicaM, Passoni D, et al. High Th1-type cytokine serum levels in patients with infectious mononucleosis. Acta Virol. 2004;48:263-266.
33. Precopio ML, Sullivan JL, Willard G, et al. Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J Immunol. 2003;170:2590-2598.
34. Islam SA, Thomas SY, Hess G, et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood. 2006:107:444-453.
35. Yamaoka KA, Claesson HE, Rosen A. Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. J Immunol. 1989;143:1996-2000.
36. Dugas B, Paul-Eugene N. Cairns J, et al. Leukotriene B4 potentiates the expression and release of Fc epsilon RII/CD23, and proliferation and differentiation of human B lymphocytes induced by IL-4. J Immunol. 1990;145:3406-3411.
37. Bailie MB, Standiford TJ, Laichalk LL, et al. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J Immunol. 1996:157: 5221-5224.
38. Byrum RS, Goulet JL, Snouwaert JN, et al. Determination of the contribution of cysteinyl leukotri-enes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase-and leukotriene A4 hydrolase-deficient mice. J Immunol. 1999; 163:6810-6819.
39. Gosselin J, Borgeat P, Flamand L. Leukotriene B4 protects latently infected mice against murine cytomegalovirus reactivation following allogeneic transplantation. J Immunol. 2005;174:1587-1593.
40. Rubin P, Mollison KW. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eico-sanoids. Prostaglandins Other Lipid Mediat. 2007;83:188-197.
41. Khanna R, Burrows SR, Kurilla MG, et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med. 1992;176: 169-176.
42. Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic Tcell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992;176:157-168.
43. Wilson AD, Morgan AJ. Primary immune responses by cord blood GD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro. J Virol. 2002;76:5071-5081.
44. Savoldo B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002; 168:909-918.